InfuSystem Holdings (INFU) Stock Price

InfuSystem Holdings Inc primarily operates in the healthcare and medical equipment industry.

The main competitors of InfuSystem Holdings Inc in the market include Option Care Health Inc and BioScrip Inc.

InfuSystem Holdings Inc, established in 2005, is a leading provider of infusion pumps and related services in the healthcare industry. With headquarters in Michigan, the company primarily caters to patients and healthcare facilities across the United States and Canada. InfuSystem offers an extensive range of infusion pumps, along with clinical and biomed support, thereby ensuring efficient and cost-effective delivery of medications needed for patient care. Over the years, the company has successfully expanded its product and service portfolio, partnering with medical professionals and hospitals to enhance patient outcomes. InfuSystem Holdings Inc has consistently demonstrated its commitment to revolutionizing healthcare delivery through innovative solutions.

InfuSystem Holdings Inc. has achieved significant milestones since its establishment. Some notable achievements include expanding its presence across the United States, enhancing its product portfolio with innovative offerings, and establishing strategic partnerships. The company has successfully gained a strong reputation for providing high-quality infusion pumps and related services to healthcare facilities and practitioners. InfuSystem Holdings Inc. has also demonstrated consistent growth and financial performance, consolidating its position as a leading provider in the medical device industry. These accomplishments exemplify the company's commitment to delivering excellent products, services, and value to its customers and stakeholders.

InfuSystem Holdings Inc, a leading provider of infusion pumps and related services, primarily operates in the United States. With offices strategically located across the nation, InfuSystem serves healthcare providers in various states and regions. The company focuses on delivering exceptional medical equipment management and infusion therapy services, supporting healthcare professionals and patients in enhancing the quality and ease of care. InfuSystem's strong presence in the United States enables them to maintain close relationships with healthcare institutions, ensuring efficient and reliable delivery of their innovative solutions.

InfuSystem Holdings Inc represents a strong commitment to delivering high-quality, patient-centric healthcare solutions. Their corporate philosophy revolves around providing comprehensive support and innovative technology to healthcare providers. With a focus on enhancing patient care, InfuSystem offers a wide range of infusion pumps, supplies, and services. Through their dedication to exceptional customer service, advanced technology, and improving patient outcomes, InfuSystem Holdings Inc continuously strives to be a reliable partner in the healthcare industry.

Analysts currently set an average price target of 15.00 USD for the InfuSystem Holdings stock (median: 15.00 USD), implying +5.9 % versus the latest price. The consensus is based on 9 analyst ratings.

InfuSystem Holdings Analyst Price Targets 2026

9 analysts currently rate the InfuSystem Holdings stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect InfuSystem Holdings to generate revenue of 145.16 M USD and earnings per share of 0.47 USD.

InfuSystem Holdings Analyst Price Targets 2026

Converted at the current exchange rate, the InfuSystem Holdings share trades at 12.62 EUR (14.16 USD).

The InfuSystem Holdings share (INFU) is listed on 2 stock exchanges, including: Frankfurt (1TZ.F).

InfuSystem Holdings Inc is a leading provider of oncology equipment and services. The company offers a wide range of products and services aimed at improving the effectiveness of cancer treatment, improving patient care, and enabling cost savings. The company operates in two main areas: infusion therapy and oncology management. The infusion therapy division includes the rental and sale of infusion pumps and accessories. These pumps are used to administer medications, fluids, and nutrients directly into the patient's bloodstream. InfuSystem offers portable pumps, among other things, that allow patients to conveniently perform their treatment from home. The pumps are equipped with state-of-the-art technology to ensure precise dosing and monitoring of the infusion process. InfuSystem's oncology management program focuses on the management and monitoring of chemotherapy-related side effects, as well as online diagnostics. The program provides close monitoring to ensure that the patient's treatment achieves the best possible results. InfuSystem works closely with treating physicians and nurses to ensure that patients receive the best possible care. In addition to these main activities, InfuSystem also offers a range of complementary products and services, including clinical consulting, education and training, disposable items, and an online platform with comprehensive training materials. These complementary services are designed to improve the effectiveness of cancer treatment and optimize patient care. To deliver its services, InfuSystem has built a network of healthcare customers who support the company as partners in treating their patients. The company's customer base includes a wide range of healthcare facilities, including hospitals, oncology practices, outpatient infusion centers, and other outpatient healthcare providers. Through strategic partnerships and acquisitions, InfuSystem has expanded its reach and ability to provide integrated solutions in the oncology market. Overall, InfuSystem has developed a business model focused on improving cancer treatment, patient care, and cost control. The company offers a wide range of products and services to meet the needs of its healthcare customers and has thus laid a strong foundation for future growth.

The expected revenue of InfuSystem Holdings is 145.16 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of InfuSystem Holdings is 9.99 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of InfuSystem Holdings is currently 29.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InfuSystem Holdings stock.

The price-to-sales ratio (P/S) of InfuSystem Holdings is currently 2.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InfuSystem Holdings stock.

The Eulerpool Quality Score for InfuSystem Holdings is 5/10.

The ISIN of InfuSystem Holdings is US45685K1025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of InfuSystem Holdings is A0NA9V. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of InfuSystem Holdings is INFU. The ticker symbol is used to trade InfuSystem Holdings shares on the stock exchange.